IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Insight Molecular Diagnostics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.89−0.12 (-3.99%)
Close on Oct 19, 2026
- Market cap
- $106.21M
- P/E (TTM)
- –
- Dividend yield
- –
Insight Molecular Diagnostics Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Laboratory Services [Member] | $4.03M | $1.86M | – | 99.4% | +116.8% |
| Kitted Products [Member] | $24.00K | $0 | – | 0.6% | – |
| Laboratory Developed Test Services [Member] | $0 | $22.00K | $36.00K | 0.0% | -100.0% |
| Pharma Services [Member] | – | $1.86M | $1.47M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| United States | $4.03M | $1.67M | $923.00K | 99.4% | +140.9% |
| Europe [Member] | $24.00K | $18.00K | – | 0.6% | +33.3% |
| Asia Pacific [Member] | $0 | $145.00K | $160.00K | 0.0% | -100.0% |
| United Kingdom | $0 | $45.00K | $409.00K | 0.0% | -100.0% |
| Spain | – | – | $11.00K | – | – |
| Germany | – | $18.00K | – | – | – |
From the segment and revenue-disaggregation notes of Insight Molecular Diagnostics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.